Last reviewed · How we verify
Hemabate (CARBOPROST)
Hemabate (generic name: CARBOPROST) is a Prostaglandin Analog Small molecule drug developed by Pfizer. It is currently FDA-approved (first approved 1979) for Postpartum hemorrhage, Pregnancy with abortive outcome.
Hemabate is a small molecule medication used to treat postpartum hemorrhage and uterine atony. It is a second-line uterotonic agent, as indicated by a randomized clinical trial (NCT03584854) conducted at Brigham and Women's Hospital.
At a glance
| Generic name | CARBOPROST |
|---|---|
| Sponsor | Pfizer |
| Drug class | Prostaglandin Analog |
| Target | Prostaglandin F2-alpha receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1979 |
Approved indications
- Postpartum hemorrhage
- Pregnancy with abortive outcome
Common side effects
- vomiting and diarrhea
- nausea
- temperature increase greater than 2° F
- flushing
- endometritis (among those with temperature elevation)
Drug interactions
- other oxytocic agents
Key clinical trials
- Cooling the Uterus in C-section After Dysfunctional Labor (NA)
- Second-Line Uterotonics in Postpartum Hemorrhage: A Randomized Clinical Trial (PHASE4)
- Comparing the Dose-response Profiles of Uterotonics After Initial Carbetocin Administration - an Ex-vivo Study in Desensitized Human Myometrium (NA)
- Carboprost (Hemabate) for Fibroid Resection (EARLY_PHASE1)
- Oxytocin Bolus Versus Infusion in Elective Cesarean Section" (PHASE4)
- The Time Point of Carboprost Methylate Administration and Perioperative Complications (NA)
- Misoprostol Versus Active Management of Labour in CS (PHASE1)
- Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hemabate CI brief — competitive landscape report
- Hemabate updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Hemabate
What is Hemabate?
What is Hemabate used for?
Who makes Hemabate?
What is the generic name of Hemabate?
What drug class is Hemabate in?
When was Hemabate approved?
What development phase is Hemabate in?
What are the side effects of Hemabate?
What does Hemabate target?
Related
- Drug class: All Prostaglandin Analog drugs
- Target: All drugs targeting Prostaglandin F2-alpha receptor
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Postpartum hemorrhage
- Indication: Drugs for Pregnancy with abortive outcome
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing